MHH researchers compared six methods for diagnosing minimal hepatic encephalopathy

The MHH joint project TARGET-MPN is investigating why myeloproliferative neoplasms (MPN) evade targeted therapy and develop into leukaemias.

Gene mutations in the RAS-MAPK signaling pathway disrupt lung development in the womb.

Specialist in herpes viruses succeeds Professor Thomas Schulz.

Scientists from RESIST and R-CUBE present their projects.

Funded with 8 million euros: The MHH is leading the RESOLVE research network, which is on the trail of the "gold standard" in AML and CLL treatment

First patient receives tricuspid valve without major surgery thanks to innovative catheter system

Cardior Pharmaceuticals is developing a drug for the treatment of heart failure. The Danish pharmaceutical group Novo Nordisk is planning to acquire…

New research centre develops innovative methods for improved healthcare.

More autonomy and planning security for state universities until the end of the decade.